Profitability
This table shows how Spectral AI compares to its competitors in net margins, return on equity, and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spectral AI | -89.85% | N/A | -104.64% |
| Competitors | -578.37% | -140.27% | -25.88% |
Ownership
67.1% of Spectral AI shares are owned by institutional investors, compared to 47.4% in the surgical and medical instruments sector. Additionally, 56.7% of shares are held by insiders, while only 15.9% is the average for competitors. This strong institutional presence suggests confidence in long-term growth.
Volatility & Risk
Spectral AI has a beta of 0.56, indicating it is less volatile than the S&P 500 by 44%. Its competitors have a beta of 0.53, showing similarly low volatility.
Analyst Ratings
Recent ratings for Spectral AI and its competitors are as follows:
| Sell | Hold | Buy | Strong Buy | Rating Score | |
| Spectral AI | 0 | 0 | 3 | 1 | 3.25 |
| Competitors | 1663 | 4406 | 8446 | 251 | 2.49 |
Spectral AI has a target price of $4.50, indicating potential growth of 265.85%. The average potential for its sector is just 17.84%, so analysts view Spectral AI more favorably.
Valuation & Earnings
This table compares gross revenue, net income, and price-to-earnings ratio for Spectral AI and its competitors.
| Gross Revenue | Net Income | P/E Ratio | |
| Spectral AI | $18.06 million | -$20.85 million | -0.92 |
| Competitors | $870.57 million | $47.37 million | -1.16 |
Spectral AI has lower revenue and earnings than its competitors, and trades at a higher price-to-earnings ratio.
Summary
Spectral AI outperforms its peers in 10 of 13 factors analyzed.
Company Profile: Spectral AI
Spectral AI specializes in AI-driven medical diagnostics aimed at improving treatment speed and accuracy for wounds, especially for burns and diabetic ulcers. Their products, including the DeepView System and DeepView SnapShot M, offer advanced analysis and portability suited for emergency care. Based in Dallas, Texas.
Receive daily news & ratings for Spectral AI – Enter your email to get concise updates and analyst ratings with MarketBeat.com’s FREE daily email newsletter.
`
